Herborium® Surpasses Million Dollar Sales Mark; Reduces Outstanding Debt and Dilution
Herborium Group, Inc. (HBRM) reported record sales exceeding $1 million for 2021, marking its fifth consecutive year of positive revenue growth. The positive trend continues into Q1 2022, with sales indicating higher figures compared to Q1 2021. Additionally, the company has reduced its debt by over $250,000, which aids in preventing future dilution and supports share price increase efforts. Herborium maintains its top position on OTC Pink Current Information and anticipates further sales growth in 2022 through upcoming projects and capital structure improvements.
- Record sales exceeding $1 million in 2021, the fifth consecutive year of positive revenue growth.
- Sales trend continued into Q1 2022, with higher figures than Q1 2021.
- Reduced debt by over $250,000, supporting share price.
- None.
Houston , Texas, May 03, 2022 (GLOBE NEWSWIRE) -- Houston, Texas,05.03/ 2022. Herborium Group, Inc. (OTC Pink: HBRM), a Botanical Therapeutics Company and the provider of unique, all botanical medicinal, beauty and wellness products with a clinically validated records of efficacy and safety, announced today that the Company ended 2021 with a record sale surpassing
This positive trend is extended to the First Quarter of 2022 that is also positive and indicates the higher sale that First Quarter of 2021
In addition, the Company significantly decreased its debt by eliminating over
Finally, the Company secured and maintained its highest standing on OTC Pink Current Information
Herborium expects to continue the sales increase in 2022 through the number of upcoming changes and special projects we will be announcing shortly.
The Company is also to continue its efforts to increase shareholder value and decrease dilution through the relevant capital structure improvements and valid partnerships.
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics company that develops, license and markets proprietary, botanical based medicinal and wellness products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products to establish and maintain a differential advantage. Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, women’s health and selected sexual disorders and has built the versatile, technologically advanced, interactive content platform to support consumer needs. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. For more information, please visit www.herborium.com, www.acnease.com, www.acnease.fr, www.acneasesp.com
Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.
Attachment
FAQ
What were Herborium's sales results for 2021?
How much debt did Herborium eliminate recently?
What is Herborium's stock symbol?
What is the current standing of Herborium on OTC markets?
What growth does Herborium expect in 2022?
